TherapeuticsMD (NASDAQ:TXMD) Research Coverage Started at StockNews.com

Posted by Doug Wharley on Jan 5th, 2025

StockNews.com started coverage on shares of TherapeuticsMD (NASDAQ:TXMD – Free Report) in a research report report published on Thursday. The brokerage issued a hold rating on the stock.

TherapeuticsMD Price Performance

Shares of NASDAQ TXMD opened at $1.47 on Thursday. The business’s 50 day moving average is $1.32 and its two-hundred day moving average is $1.58. TherapeuticsMD has a 52-week low of $0.70 and a 52-week high of $2.75.

Institutional Investors Weigh In On TherapeuticsMD

A hedge fund recently raised its stake in TherapeuticsMD stock. Clearline Capital LP lifted its stake in TherapeuticsMD, Inc. (NASDAQ:TXMD – Free Report) by 18.9% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 636,622 shares of the company’s stock after purchasing an additional 101,282 shares during the period. Clearline Capital LP owned about 5.52% of TherapeuticsMD worth $1,025,000 at the end of the most recent quarter. 30.74% of the stock is owned by institutional investors and hedge funds.

About TherapeuticsMD

(Get Free Report)

TherapeuticsMD, Inc operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors.